Researchers at the University of California, Davis have developed a biologic treatment for mitigating pain and treating acute urinary tract infections (UTIs) in canines.
Antibiotic resistance is an ongoing issue for both companion animals and humans. In humans, bacterial urinary tract infections (UTIs) are the second most common infectious disease. Treatment typically includes a form of antimicrobial therapy. Similar UTIs also often present in otherwise healthy animals. Because of increased resistance to antibiotics, that treatment option has shown decreasing efficacy in treating recurrent UTIs. Alternative treatments or prevention techniques have been introduced. But some, such as the use of cranberry extract, cranberry juice, or other probiotics, have not yet proven to be more effective than a placebo in test cases.
Researchers at the University of California, Davis have discovered a biotic strain that mitigates and treats acute urinary tract infections in canines. This new treatment utilizes a strain of Escherichia coli (E.coli) to mitigate, ameliorate, or inhibit clinical signs of UTI, and decrease pain associated with UTIs. This method can be administered via one or more intravesicular instillations directly into the bladder of the canine. This treatment could eventually delay or completely avoid recurrent UTIs in canines with a history of multiple infections. There is also the potential to apply this treatment to humans.